Biogen Alzheimer’s Drug Subject of New House Committee Probe

Two key House Democrats are opening a joint committee investigation into Biogen Inc.’s new Alzheimer’s drug, saying its approval and high cost create questions about the regulatory process.

“We have serious concerns about the steep price of Biogen’s new Alzheimer’s drug Aduhelm and the process that led to its approval despite questions about the drug’s clinical benefit,” Oversight and Reform Committee Chairwoman Carolyn Maloney and Energy and Commerce Committee Chairman Frank Pallone said in a statement Friday.